Loading
A phase 2 trial of Trastuzumab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC is a phase 2 interventional study registered as NCT05246514 by AstraZeneca, with 72 participants enrolled, started 2022-07-13 and due to reach its primary completion in 2024-11-04. Interventions recorded: Trastuzumab deruxtecan. Conditions listed: HER2-mutant Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
72 enrolled.
95% CI 44.7 to 68.6; Figures from the ClinicalTrials.gov results section (first posted 2024-12-04), not from a publication
Source95% CI 17.5 to NA; Figures from the ClinicalTrials.gov results section (first posted 2024-12-04), not from a publication
Source95% CI 9.9 to NA; Figures from the ClinicalTrials.gov results section (first posted 2024-12-04), not from a publication
SourceShares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares HER2-mutant non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, AstraZeneca, Antibody-drug conjugate (ADC).
Shares Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial, Small-cell lung cancer, Non-small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.